Aurobindo gets Dutch board nod for Simvastatin
Aurobindo Pharma has received the marketing authorisation approval for a lipid-lowering agent, Simvastatin, from Medicines Evaluation Board (MEB), Netherlands, according to a statement from the company.
By TNN |
HYDERABAD: Aurobindo Pharma has received the marketing authorisation approval for a lipid-lowering agent, Simvastatin, from Medicines Evaluation Board (MEB), Netherlands, according to a statement from the company.
This is the third formulation approval received from the Dutch board for a product developed in-house by Aurobindo and fifth such approval in Europe for the company.
The approval will enable Aurobindo to obtain similar marketing authorisation for Simvastatin tablets in other countries of the European Union through mutual recognition procedure, the statement added. The company has already filed marketing approval for 26 products in various EU countries.
This is the third formulation approval received from the Dutch board for a product developed in-house by Aurobindo and fifth such approval in Europe for the company.
The approval will enable Aurobindo to obtain similar marketing authorisation for Simvastatin tablets in other countries of the European Union through mutual recognition procedure, the statement added. The company has already filed marketing approval for 26 products in various EU countries.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
